T Cell Redirection As a New Standard of Care for Relapsed Multiple Myeloma: Impact on Inpatient Capacity, Financial Burden and Infrastructural Requirements in Germany
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Soekojo C, Chng W
. Treatment horizon in multiple myeloma. Eur J Haematol. 2022; 109(5):425-440.
DOI: 10.1111/ejh.13840.
View
2.
Mateos M, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M
. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia. 2022; 36(5):1371-1376.
PMC: 9061296.
DOI: 10.1038/s41375-022-01531-2.
View
3.
Gandhi U, Cornell R, Lakshman A, Gahvari Z, McGehee E, Jagosky M
. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019; 33(9):2266-2275.
PMC: 6820050.
DOI: 10.1038/s41375-019-0435-7.
View
4.
Munshi N, Anderson Jr L, Shah N, Madduri D, Berdeja J, Lonial S
. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021; 384(8):705-716.
DOI: 10.1056/NEJMoa2024850.
View
5.
Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka A
. Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma. Future Oncol. 2024; 20(18):1221-1235.
PMC: 11333973.
DOI: 10.2217/fon-2023-0954.
View